The distinctive nature of HER2-positive gastric cancers
Authors:
- 1 March 2015
- journal article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 41 (3) , 271-273
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- HER2 Expression and PI3K-Akt Pathway Alterations in Gastric CancerDigestion, 2014
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperoneJournal of Cell Biology, 2004
- c-erb B-2 Expression Is Associated with Tumor Location and Venous Invasion and Influences Survival of Patients with Gastric CarcinomaInternational Journal of Surgical Pathology, 2002
- Nuclear localization of EGF receptor and its potential new role as a transcription factorNature Cell Biology, 2001
- The basic biology of HER2Annals of Oncology, 2001
- Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical StainOncology, 1996